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PURPOSE. To determine whether human retinal endothelial cells (HRECs) express the
endothelial cell protein C receptor (EPCR) and to realize its potential as a targeting moiety by
developing novel single and dual corticosteroid–loaded functionalized liposomes that exhibit
both enhanced uptake by HRECs and superior biologic activity compared to nontargeting
liposomes and free drug.
METHODS. EPCR expression of HRECs was investigated through flow cytometry and Western
blot assays. EPCR-targeting liposomes were developed by functionalizing EPCR-specific
antibodies onto liposomes, and the uptake of liposomes was assessed with flow cytometry
and confocal laser scanning microscopy. The therapeutic potential of EPCR-targeting
liposomes was determined by loading them with prednisolone either through bilayer
insertion and/or by remote loading into the aqueous core. The carrier efficacy was assessed in
two ways through its ability to inhibit secretion of interleukins in cells stimulated with high
glucose and angiogenesis in vitro by using an endothelial cell tube formation assay.
RESULTS. HRECs express EPCR at a similar level in both human aortic and umbilic vein
endothelial cells. The EPCR-targeting liposomes displayed at least a 3-fold higher uptake
compared to nontargeting liposomes. This enhanced uptake was translated into superior anti-
inflammatory efficacy, as the corticosteroid-loaded EPCR-targeting liposomes significantly
reduced the secretion of IL-8 and IL-6 and inhibited the development of cell tube formations
in contrast to nontargeting liposomes.
CONCLUSIONS. We show that HRECs express EPCR and this receptor could be a promising
nanomedicine target in ocular diseases where the endothelial barrier of the retina is
compromised.
Keywords: retina, liposomes, EPCR, corticosteroids, endothelial cells
Diabetic retinopathy is the most common microvascularimplication of diabetes mellitus and corresponds to the
leading cause of visual impairment in adults between 20 and 65
years old in the developed world.1,2 Its hallmark features
include weakening of tight junctions, formation of microaneu-
rysms on the retinal capillaries, pericyte loss, endothelial cell
loss, retinal ischemia with secondary preretinal neovasculariza-
tion, capillary leakage, and macular edema.3–5 Breakdown of
the blood-retina barrier in diabetic retinopathy is a character-
istic feature of the more severe levels of retinopathy that may
provide a special opportunity to deliver drugs to the
endothelium and other components of the retina, be it from
the luminal or abluminal side of the vessel wall. The exposed
endothelium presents an opportunity for targeted drug delivery
at the site of disease.
Endothelial cell protein C receptor (EPCR/CD201) is a
transmembrane glycoprotein that facilitates the activation of
protein C and thereby regulates the anticoagulation pathway.6,7
It has been shown to be a critical for life receptor, if its
expression is knocked down or compromised due to patho-
logic reasons.8–10 A soluble form, produced by metalloprotease
cleavage from the cell membrane,11 works along with the
membrane-bound EPCR in the pathophysiology of sepsis and
inflammation in a poorly understood manner.6,12 EPCR was
initially thought to be expressed only on the endothelium of
large vessels but was then found on smooth muscle cells,
neutrophils, keratinocytes, and microvascular endothelia such
as that of the brain capillaries.13–15 To the best of our
knowledge, it has not previously been identified on human
retinal endothelial cells (HRECs).
In this study, we investigated the expression of EPCR on
HRECs and the potential of this receptor as a target for drug
nanocarriers by using unilamellar liposomes as a model system.
Liposomes, uni- or multi-lamellar vesicles comprised of
phospholipids and, frequently, cholesterol, have a range of
attractive properties as drug carriers, including ease of
assembly, low cytotoxicity, and a high loading capacity for
both hydrophobic and hydrophilic drugs.16,17 Liposomes have a
history of clinical approval18 and have demonstrated promising
intraocular results (e.g., sustained drug release, high therapeu-
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tic efficacy, and reduced cytotoxicity of the drugs).19,20 Here,
we report EPCR expression on HRECs in comparison to human
aortic endothelial cells (HAECs) and human umbilical vein
endothelial cells (HUVECs). We determined the targeting
efficiency of functionalized liposomes with EPCR-specific
monoclonal antibodies on HRECs and HAECs. Furthermore,
we assessed the anti-inflammatory efficacy of EPCR-targeting
liposomes when loaded with the corticosteroid prednisolone
(either prednisolone 21-hemisuccinate sodium salt [PH] and/or
prednisolone 21-palmitate [PP]) through the inhibition of IL-8
and IL-1b and IL-6 expression in stimulated HRECs, as well as
the ability to inhibit angiogenesis in vitro using an endothelial
cell tube formation assay.
MATERIALS AND METHODS
Materials
Cholesterol (Chol), 1,2-dipalmitoyl-sn-glycero-3-phosphocho-
line (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-(methoxy[polyethylene glycol]-2000) (PEG) and 1,2-distearo-
yl-sn-glycero-3-phosphoethanolamine-N-(maleimide[polyethy-
lene glycol]-2000) (maleimide) were all purchased from Avanti
Polar Lipids (Alabaster, AL, USA). 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-lissamine (DPPE-Atto) was purchased
from Atto-TEC (Siegen, Germany). Prednisolone, PH, mannitol,
HEPES, NaCl, N,N0-dicyclohexylcarbodiimide, 4-(dimethylami-
no)pyridine, palmitic acid, and all organic solvents were
purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA).
ELISA kits for IL-1b, IL-6, and IL-8, along with the Human
Cytokine Array kit were obtained from R&D Systems Inc.
(Minneapolis, MN, USA), and the Matrigel matrix was
purchased from Corning (Flintshire, UK). The monoclonal
antibodies Alexa Fluor 488 rat anti-human CD201 clone RCR-
252, Alexa Fluor 488 rat IgG1 j isotype control clone R3-34,
and rat anti-human CD201 clone RCR-252 (anti/EPCR) were
purchased from BD Biosciences (San Jose, CA, USA).
PP Synthesis, Purification, and Characterization
The synthesis of PP was achieved using Steglich esterification.
Prednisolone, palmitic acid, N,N0-dicyclohexylcarbodiimide,
and 4-(dimethylamino)pyridine (1:1:2:2 molar ratio) were all
dissolved in excess dichloromethane under an N2 atmosphere
and left stirring at room temperature for 18 hours. The reaction
was followed by thin-layer chromatography using a chloro-
form:methanol (95:5) mobile phase. PP appeared as a streaked
spot close to the baseline. Dichloromethane was evaporated
under rotation and reduced pressure to leave a crude product.
Crude product was redissolved in a chloroform:methanol
(95:5) mixture and purified on a silica gel column by using a
chloroform:methanol (95:5) mobile phase. The resulting
purified PP had a high yield (>85%) and high purity (>97%).
Purity was determined by both analytic high pressure liquid
chromatography (HPLC) and 1H nuclear magnetic resonance
(NMR) spectroscopy. 1H NMR (CHCl3-D) key characteristic
peaks include the following: d 0.88 (t, 3H, 37), 0.98 (s, 3H, 18),
1.25 (s, 24H, 25–36), 1.45 (s, 3H, 19), 4.48 (m, 1H, 11), 4.87 (d,
1H, J¼ 17.4 Hz, 21), 4.97 (d, 1H, J¼ 17.4 Hz, 21), 6.00 (t, 1H,
4), 6.27 (dd, J¼ 10.09, 1.89 Hz, 2), and 7.27 (d, J¼ 10.1 Hz, 1).
The remaining corticosteroid ring 1H chemical shifts followed
similar values (e.g., d 1.6–2.6 covers protons at 6, 7, 8, 12, 14,
15, 16, and 23) as previously reported for prednisolone, similar
corticosteroids, and functionalized corticosteroids where
functionalization occurred at position 21 (see Supplementary
Fig. S1 for 1H NMR spectrum and atom numbering).21–23
Liposome Preparation and Loading
All liposomes were prepared by mixing the lipids in a tertiary
butanol:water (9:1) mixture and lyophilized overnight in a
Christ Epsilon 2-4 LSCplus freeze dryer (Buch & Holm, Herlev,
Danmark). Subsequently the lipid mixtures were rehydrated
with 10 mM HEPES saline buffer or with a 200 mM calcium
acetate buffer (Sigma-Aldrich Corp.) for the remote loading of
PH. Lipid suspensions were prepared at 15 mM and hydrated at
608C with gentle vortexing for 60 minutes, followed by
extrusion through a 100-nm filter at 608C.24 For the liposome
formulations with membrane-loaded PP, the extrusion was
performed in 3 steps through 400-nm, 200-nm, and finally
through 100-nm filters. Remote loading was performed using a
protocol previously described.25,26 Briefly, the liposomes were
subjected to 3 repeated 1-hour dialysis cycles by using a ratio of
liposome dispersion to dialyzing medium (5% glucose) 1:200,
followed by a forth dialysis step overnight of 1:400. PH was
dissolved in 5% glucose and was mixed with liposomes in a
drug to lipid ratio of 1:2. Remote loading was achieved by
incubation of the liposomes with the drug for 20 minutes at 60
to 658C, with continuous stirring. Nonencapsulated drug was
removed by 2-step dialysis (dialysis tubing, MWCO 10 kDa;
Sigma-Aldrich Corp.) using a ratio of 1:500 sample to diluent
(10 mM HEPES, pH 7.4, 150 mM NaCl), with the first step
lasting for 4 hours at 48C and the second step overnight at 48C.
For the uptake studies, the different systems that we prepared
were of the following molar ratios: (1) DPPC/Chol/PEG/
maleimide/DPPE-Atto, 55.92:40:3:1:0.08, (2) DPPC/Chol/
DPPE-Atto, 59.92:40:0.08, and (3) DPPC/Chol/PEG/DPPE-Atto,
55.92:40:4:0.08. For the flow cytometry experiments, DPPE-
Atto 655 was used and for the microscopy images, DPPE-Atto
488 was used. We did not observe any size or charge
differences of the liposomal carriers when replacing fluoro-
phores. For the efficacy studies, we removed fluorophore-
conjugated phospholipids so the formulations for these
experiments were DPPC/Chol/ PEG/maleimide (56:40:3:1)
and DPPC/Chol/PEG (56:40:4), and we included an extra
formulation of DPPC/Chol/ PEG/maleimide/PP (51:40:3:1:5)
with a 5% molar concentration of PP in the bilayer. See Tables 1
and 2 for all liposome formulations.
Liposome Characterization
The diameter and surface charge of the liposomes were
measured on a Brookhaven ZetaPALS zeta potential analyzer
(New York, NY, USA) as previously described.27 Briefly,
diameters (measured by dynamic light scattering) and zeta
potentials were measured in 10 mM HEPES in a 5% glucose
solution. Phospholipid concentrations were determined by
quantifying the phosphorous content in the liposome samples
by using inductively coupled plasma mass spectrometry. For
further confirmation of the liposome size distribution
measured by dynamic light scattering, we used Cryo-
transmission electron microscopy (TEM). For each experi-
ment, 3 lL of lipid dispersions at a concentration of 3 mM was
placed on a lacy carbon 300 mesh copper TEM grid, blotted
and plunge frozen in liquid ethane by using a FEI Vitrobot
Mark IV (Thermo Fisher Scientific, OR, USA). Samples were
transferred to the TEM at1758C by using a Gatan 626 single
tilt cryo-transfer holder (Gatan, Inc., Pleasanton, CA, United
States) and were imaged using a FEI Tecnai G2 20 TWIN TEM
operated at 200 keV in low dose mode with a FEI high-
sensitive 4k34k Eagle camera. The loading of both PH and PP
was quantified by reverse phase HPLC, and the loading
efficiency was calculated by the drug-to-lipid ratios before and
after purification.
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Liposome Functionalization
Rat anti-human CD201 clone RCR-252 and isotype IgG control
(rat IgG1; BD Biosciences) antibodies were diluted to a final
concentration of 0.45 mg/mL in 0.2 M sodium borate buffer
(pH 8.5) mixed with 2-iminothiolane (Traut’s reagent; Sigma-
Aldrich Corp.) at a molar ratio of 1:20. The thiolation reaction
proceeded for 60 minutes at room temperature, and the
thiolated antibodies were then transferred to Amicon Ultra 4-
mL spin filters (MWCO 30 kDa; Merck Life Science, Søborg,
Denmark). The spin filters were filled with cold 10 mM HEPES
buffer and centrifuged at 2500g for 30 minutes at 48C. This
process was repeated 2 times to purify the thiolated antibodies
from unreacted 2-iminothiolane. The thiolated antibodies were
immediately mixed with DSPE-PEG-maleimide liposomes in a
molar ratio of 10:1 (of the available maleimide groups) and the
liposome-antibody mixture was incubated overnight on a
rocking table (180 rpm) in the dark to allow for conjuga-
tion.28,29 After the incubation, the antibody-functionalized
liposomes were separated from the nonbound antibodies by
size-exclusion chromatography using a Sepharose CL-4B
column (Sigma-Aldrich, Corp.) with a 10 mM HEPES, 150
mM NaCl (pH 7.4) buffer as the fluid phase. The size-exclusion
chromatography fractions were analyzed by the BCA assay
(Thermo Fisher Scientific, Hvidovre, DK) for the antibody
concentration, and the fractions containing antibody-function-
alized liposomes were up-concentrated using Amicon Ultra 4-
mL spin filters (MWCO 30 kDa; Merck Life Science) at 2500g
and at 48C.
Release Profile In Vitro
The dialysis method was used to characterize the in vitro
release behavior of the PH-loaded liposomes. We loaded 1 mL
of 6 mM liposomes into dialysis bag (MWCO 10 kDa) and
incubated them in 9 mL of 10 mM HEPES saline buffer at 378C
with continuous stirring for 120 hours. At predetermined
timepoints, 200 lL of release media was sampled and equal
volumes of fresh media was added. The cumulative release of
PH was calculated after analyzing the samples by HPLC (n¼4).
Cell Culture
HRECs were purchased from Innoprot (Bizkaia, Spain), and the
HAECs and HUVECs were purchased from LGC Standards
GmbH (Wesel, Germany). The cells were grown to 85 to 90%
confluency in the endothelial cell medium (Innoprot) supple-
mented with 5% (vol/vol) fetal bovine serum, 1% (vol/vol)
penicillin/streptomycin in an environment of 95% O2 and 5%
CO2. For the endothelial cell tube formation assay, the cells
were cultured on Matrigel matrix (Corning). 96-well plates
were coated with Matrigel (50 lL/well) at 48C and were
incubated at 378C for 30 minutes. Subsequently, 15 3 103
HRECs were seeded in each well with a final volume of 200 lL
endothelial cell medium.
Cell Viability (MTS Assay)
Cell proliferation and viability were evaluated by an MTS assay.
HRECs, HAECs, and HUVECs were seeded into 96-well plates at
a density of 3 3 103 cells per well per 100 lL. Twenty-four
hours later, the cells were exposed to PH at concentrations
from 1 nM to 1 mM for 4 hours. The cells were incubated for
48 hours and then 20 lL MTS reagent was added to each well.
The absorbance at 490 nm was measured by a microplate
reader 4 hours later. The same process was followed in order to
determine the cytotoxicity of our liposomal system. The cells
were incubated with liposomes at lipid concentrations from
100 nM to 500 lM.
Detection of EPCR in HRECs by Flow Cytometry
and Western Blot
In order to determine whether HRECs express EPCR or not, we
used flow cytometry and Western blot assays. For the flow
cytometry, HRECs, HAECs, and HUVECs were seeded in T75
flasks (Thermo Scientific) and grown to 85 to 90% confluency
in the endothelial cell medium (Innoprot) supplemented with
5% (vol/vol) fetal bovine serum and 1% (vol/vol) penicillin/
streptomycin in an environment of 95% O2 and 5% CO2. When
the cells reached confluency, they were washed in PBS, 3 mL
of trypsin-EDTA was then added to each flask, and flasks were
incubated for 5 minutes. The cell suspensions were centri-
fuged (200g, 208C, 5 minutes), the collected cell pellet was
resuspended in cold PBS, and this process was repeated once
more. The washes were collected in Eppendorf (Hørsholm,
Denmark) tubes with a concentration of 53 105 cells per tube
per 500 lL of PBS. Cells were then incubated with 10 lg/mL of
Alexa Fluor 488 rat anti-human CD201 clone RCR-252 or Alexa
Fluor 488 rat IgG1 j isotype control clone R3-34 for 30 minutes
at 48C (BD Biosciences). The cell suspensions were washed
twice with PBS, were transferred to flow cytometry tubes, and
analyzed using a BD Accuri C6 autosampler flow cytometer
(BD Biosciences). In each experiment, 20,000 events were
analyzed and at least 3 independent experiments were
performed.
For the Western blot assay, the HRECs and the HAECs were
seeded in T25 flasks (Thermo Scientific) and grown to 85 to
TABLE 2. Liposome Formulations and Characteristics Used for the Efficacy Studies
Formulations Abbreviation Size, nm PDI Zeta Potential, mV
DPPC:Chol:PEG (56:40:4) þ PH P-NL1 149.5 6 1.1 0.04 6 0.03 16.82 6 1.12
DPPC:Chol:PEG:maleimide-anti/EPCR (56:40:3:1) þ PH EPCR-NL1 162.7 6 0.9 0.05 6 0.03 14.19 6 1.32
PP:DPPC:Chol:PEG:maleimide-anti/EPCR (5:51:40:3:1) þ PH EPCR-NL2 101.2 6 1.3 0.03 6 0.01 15.49 6 1.71
DPPC:Chol:PEG:maleimide-anti/EPCR (56:40:3:1) EPCR-NL 160.3 6 1.5 0.03 6 0.02 15.93 6 1.65
TABLE 1. Liposome Formulations and Characteristics Used in the Uptake Studies
Formulations Abbreviation Size, nm PDI Zeta Potential, mV
DPPC:Chol:PEG:DPPE-Atto (55.92:40:4:0.08) P-NL 157.5 6 1.4 0.03 6 0.02 17.84 6 0.85
DPPC:Chol:DPPE-Atto (59.92:40:0.08) B-NL 153.1 6 0.9 0.07 6 0.01 0.96 6 2.1
DPPC:Chol:PEG:maleimide:DPPE-Atto-anti/EPCR (55.92:40:3:1:0.08) EPCR-NL 162.5 6 1.4 0.02 6 0.01 16.09 6 1.62
DPPC:Chol:PEG:maleimide:DPPE-Atto-isotype (55.92:40:3:1:0.08) Iso-NL 161.3 6 1.7 0.07 6 0.03 14.21 6 1.17
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90% confluency. For transfection, when cells reached 70 to
80% confluency, they were incubated with EPCR/PROCR
silencer predesigned siRNA (Thermo Fisher Scientific) Lipo-
fectamine 2000 (Thermo Fisher Scientific) complexes. Briefly,
500 pmol of siRNA was diluted in 250 lL Opti-MEM I reduced
serum medium and 5 lL Lipofectamine 2000 was diluted in
250 lL of Opti-MEM I reduced serum medium, and both
solutions were incubated for 15 minutes at room temperature.
After the 15 minute incubation, the diluted siRNA and the
diluted Lipofectamine 2000 were combined and incubated for
15 minutes at room temperature so as to allow complexes to
form. Subsequently, the siRNA-Lipofectamine 2000 complexes
were added to the T25 flasks at a total of 5 mL medium and
incubated at 378C in a humidified CO2 incubator for 24 hours.
Then, the cells were washed 2 times with cold PBS, lysed with
lysis buffer (25 mM Tris-HCl; pH, 7.4; 0.15 M NaCl; 1% Triton X-
100) with complete Mini Protease Inhibitor Cocktail (Sigma-
Aldrich Corp.) and Phosphatase Inhibitor Cocktail 2 (Sigma-
Aldrich Corp.), then placed on a shaker at 48C for 30 minutes.
After centrifugation at 12,000g for 10 minutes, the protein
concentration of the supernatant was measured by BCA assay
(Thermo Fisher Scientific). Subsequently, equal amounts of 20
lg of protein were loaded and separated by 4 to 12% Bis-Tris
gel electrophoresis (Thermo Fisher Scientific). The proteins
were transferred to a nitrocellulose membrane (Thermo Fisher
Scientific). Following the transfer, the immunoblot was
incubated with Odyssey blocking buffer (LI-COR Biosciences,
Cambridg, UK) at room temperature for 1 hour with agitation.
EPCR was detected by monoclonal rat anti-EPCR/CD201
antibody (RCR-252) (Abcam, Cambridge, UK) at 1:50 dilution
in which the membrane was incubated overnight at 48C. The
membrane was washed 3 times by tris-buffered saline and
Tween 20 for 5 minutes, and then the second antibody (goat
anti-rat IgG [HþL] Cross-Adsorbed Secondary Antibody, DyLight
800; Thermo Fisher Scientific), at 1:10,000 dilution, was
incubated at room temperature for 1 hour. The membrane
was washed 3 times with tris-buffered saline and Tween 20,
and the protein bands were visualized by Odyssey Fc Imaging
System (LI-COR Biosciences).
Quantification of Liposome Uptake by Cells Using
Flow Cytometry
We evaluated the uptake of fluorescently labeled liposomes by
endothelial cells with flow cytometry. HRECs, HAECs, and
HUVECs were seeded at a density of 123 105 cells per well in
12-well plates (Thermo Scientific) in 1 mL of the culture
medium at 378C under an atmosphere with 5% CO2. After 24
hours, the cells were incubated with the Atto 655–labeled
carriers at a liposomal concentration of 75 lM in medium for 1
hour, 2 hours, or 3 hours. For the experiments where we
blocked EPCR, we added 5 lg of rat anti-human CD201 clone
RCR-252 in each well and incubated for 20 minutes. Then, we
added the liposomes without washing off the antibody.
Subsequently, the cells were washed with PBS and then
trypsinized. The cell suspension was centrifuged (200g, 208C,
5 minutes), and then the collected cells were resuspended in 1
mL PBS. The latter process was repeated 3 times, and then the
cells were transferred to flow cytometry tubes and analyzed
using the Gallios flow cytometer (Beckman-Coulter, Copenha-
gen, DK). Cells were gated based on the forward/side scatter
plot to eliminate cell debris from the subsequent analysis. At
least 10,000 events were analyzed in each experiment and a
minimum of three independent experiments were performed.
The fluorescence intensity of the liposome treated cells was
corrected based on the autofluorescence of nontreated cells
and the resulting data was analyzed using FlowJo software
(FlowJo LLC, Oregon, USA).
Confocal Laser Scanning Microscopy
Further estimation of the uptake of the different carriers was
performed by confocal laser scanning microscopy. In that case,
25 3 103 cells were seeded in a l-Slide 8 well (ibidi GmbH,
Planegg, Germany) in 300 lL of culture medium as a 2D
culture or on Matrigel matrix. After 24 hours, the cells were
incubated with 75 lM of the different Atto 488–labeled carriers
for 3.5 hours. Subsequently, 20 mL of TO-PRO-3 (1 lM; Thermo
Fisher Scientific) dye was added to stain the nuclei, and the
suspension was reincubated for an additional 30 minutes. The
medium was then removed, and the cells were washed twice
with 300 lL PBS, before they were fixed with 4% paraformal-
dehyde for 10 minutes at room temperature and washed again
twice with 300 lL of PBS. After fixation, and only for the 2D
cultured cells, 300 lL of Phalloidin-TRITC in 10 mM HEPES
(1:300; Sigma-Aldrich) was added to each well and incubated
for 1 hour at room temperature. Eventually, each well was
washed twice with PBS, and confocal imaging was performed
using a Leica TC SP5 confocal laser scanning microscope (Leica
Microsystems GmbH, Wetzlar, Germany).
Stimulation of Cells by High Glucose and Cytokine
Quantification
To study the anti-inflammatory efficacy of our carrier, we
stimulated an inflammatory response in the cells by culturing
them in high glucose conditions. For these studies, only the
primary cell lines were used. HRECs and HAECs were seeded
in 12-well plates at a concentration of 30 3 103 cells/well
under either normal glucose (5.5 mM), mannitol (20 mM,
mannitol-osmolarity control), or high glucose (25 mM)
conditions for up to 3 days. Twenty-four hours after having
been seeded in high glucose, the cells were treated with the
following: (1) 25 lM prednisolone hemisuccinate in the form
of free drug, (2) 25 lM prednisolone hemisuccinate encapsu-
lated in the targeting liposomal system, with or without PreP
on the membrane, or (3) 25 lM prednisolone hemisuccinate
encapsulated in nontargeting liposomes (P-NL) for 4 hours,
then washed and incubated at 378C with 5% CO2. Subsequent-
ly, we collected the cell supernatant 24 hours following the
treatment, centrifuged them at 3000g for 5 minutes, and saved
the samples at808C. New medium was added to the wells and
incubated at 378C with 5% CO2 for another 24 hours when we
again collected the supernatant, 48 hours after treatment.
Concentrations of IL-1b, IL-8, and IL-6 protein in culture
supernatant were determined using an ELISA.
Endothelial Cell Tube Formation Assay
Angiogenesis was studied by assessment of tube formation on
HRECs seeded onto Matrigel matrix (Corning), as has been
previously described.30 After coating the 96-well plates with
Matrigel, 153 103 HRECs were seeded in each well with a final
volume of 200 lL. To determine the effect of the drug and the
liposomes on the capillary tube formation, HRECs were
incubated under 6 different conditions from the onset of the
culture: (1) no treatment (control), (2) empty liposomes, (3) 50
lM prednisolone hemisuccinate as free drug, (4) 50 lM
prednisolone hemisuccinate encapsulated in the targeting
liposomal system, with or without PP, or (5) 50 lM
prednisolone hemisuccinate in nontargeting liposomes.
Phase-contrast images (53magnification) of the center of each
well were taken 4 hours, 8 hours, and 24 hours after seeding
the cells, and tube formation was quantified using the
Angiogenesis Analyzer tool for ImageJ (reported as the total
length of the tubelike formations and the number of segments
formed) (National Institutes of Health, Bethesda, MA, USA).
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Cell Experiment Statistics
Data were expressed as mean 6 SEM and a one-way ANOVA
with a confidence level of 95% (a ¼ 0.05), followed by a
Tukey’s multiple comparison post hoc test (P < 0.05) were
used in order to analyze significant differences in the in vitro
assays.
RESULTS
Characterization of Liposomes
Size distribution, polydispersity index (PDI), and zeta-potential
were measured for each formulation (see Tables 1 and 2), and
the structure of the empty and loaded liposomes was further
characterized by cryo-TEM imaging (Fig. 1A). Liposome
formulations without PP had diameters ranging from 150 to
165 nm, and from the cryo-TEM images, it was observed that
most of the liposomes were unilamellar and spherical in shape.
The precipitation of PH in the core of the liposomes was also
observed. The formulation with PP had slightly smaller
diameters of approximately 100 nm. The loading efficiency
for PP was 45% (6 3.2%), whereas for PH was 70% (6 2.8%).
Moreover, the cumulative release profile of PH for both
antibody functionalized and nonfunctionalized liposomes
showed sustained release for 5 days without any initial burst,
but with a slightly higher release rate for the nonfunctionalized
liposomes compared to the EPCR-targeting ones (Fig. 1B). PH
release profiles from targeting and nontargeting liposomes
could be fitted best with a first order exponential (P-NL1, R2¼
0.969; EPCR-NL1, R2¼ 0.947), which indicates that the release
rate of drug is dependent on the drug concentration.31
EPCR Expression in HRECs
In order to determine whether or not HRECs express EPCR, we
selected 2 endothelial cell types (HUVECs and HAECs7) that
have already shown strong expression of the receptor, and we
compared all 3 with flow cytometry. From the analysis of these
experiments, we observed a shift of 2 orders of magnitude in
the median fluorescent intensity (MFI) levels of the HRECs that
were incubated with the anti-EPCR monoclonal antibody,
compared to the isotype-treated cells or the nontreated ones.
This shift was similar to shifts observed for HAECs and
HUVECs, which can be approximated as 99.9% of HRECs
expressing EPCR at similar levels to the other 2 endothelial cell
lines (Fig. 2A). See Supplementary Fig. S2 for fluorescence-
activated cell sorting scatter plots.
The comparison between HRECs and HAECs through
Western blots indicated similar immunoblotting for both
endothelial cell types at 49 kDa and 38 kDa (Fig. 2B). The
double band can be explained by the fact that EPCR has 4 N-
linked glycosylation sites that can be heterogeneously modi-
fied, which results in a glycosylated mass of 49 kDa that
FIGURE 1. Liposome characteristics. (A) Cryo-TEM image of nonloaded (EPCR-NL) and PH-loaded EPCR-targeting (EPCR-NL1) liposomes. Scale bar:
100 nm. (B) Cumulative PH release profile of EPCR-NL1 and P-NL1 liposomes. The dashed lines represent first order fits of each release profile.
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varies among cell lines.32 As another approach to confirm the
cell surface expression of EPCR from HRECs, we transfected
HRECs with EPCR knockdown siRNA and immunoblotted the
total protein extract (~20 lg) of both transfected and
nontransfected HRECs. In this case, we can see strong binding
of the anti-EPCR monoclonal antibody at 49 kDa and 38 kDa for
HRECs cells, but for the transfected cells, there is a 2-fold
reduction at the normalized signal of the 49 kDa band and a
noticeable decrease at the 38 kDa band (Fig. 2C).
EPCR-Targeting Effects on Cellular Uptake
Once we had established the expression of EPCR on the
surface of HRECs, we investigated the potential of targeting
this receptor with antibody-functionalized liposomes. For the
FIGURE 2. EPCR expression in endothelial cells. (A) Flow cytometry analysis of EPCR expression in HRECs. Cells were incubated with isotype
control IgG or anti–EPCR monoclonal antibody (RCR-252), both conjugated with Alexa Fluor 488, and the autofluorescence of the cells is indicated
from the nontreated ones. EPCR expression estimated by MFI determined by flow cytometry analysis from 3 independent experiments is shown on
the left, and example flow cytometry histograms from 1 of the experiments on the right. (B) Immunoblotting of cell surface EPCR by RCR-252.
Western blot (left) where lanes 1–3 represent HRECs and lanes 4–6 represent HAECs. Densitometry of Western blot data is show on the right. (C)
Western blot (left) where lanes 1–3 represent HRECs and lanes 4–6 represent transfected HRECs with EPCR knockdown siRNA. Densitometry of
this is shown on the right.
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first set of experiments, liposomes functionalized with either
the EPCR-specific antibody or isotype were incubated for 4
hours with cells. As a second negative control, EPCR was
blocked by incubating the cells with the monoclonal anti-EPCR
antibody before adding the EPCR-targeting liposomes. EPCR-
targeting liposomes associated strongly with both HRECs and
HAECs, which corresponded to an 8.3-fold increase in the MFI
compared to isotype IgG liposomes and a 5.2-fold increase
compared to the cells with the blocked receptor (Fig. 3A).
Subsequently, we wanted to compare the binding and uptake
of the EPCR-targeting liposomes with other nontargeting
liposomes, so we made nonfunctionalized/blank (B-NL) and
P-NL liposome formulations. We then performed a time study
in order to investigate how uptake evolves with different
incubation times. Analysis of the flow cytometry data showed
that the EPCR-targeting liposomes (EPCR-NL) displayed signif-
icantly higher uptake with the HRECs and HUVECs after 1 hour
of incubation (Fig. 3B) than P-NL (3.2-fold) and B-NL (5.7-fold).
The results for HAECs were similar, with EPCR-NL being higher
than P-NL (2.3-fold) and B-NL (4.6-fold). Furthermore, we
found that the longer the incubation time, the higher the
uptake by cells with all the different formulations. However,
EPCR-NL repeatedly showed more than 3-fold higher MFI
compared to P-NL after 2 hours and 3 hours of incubation with
HRECS and more than 6-fold higher than B-NL. Similar behavior
was observed for HAECs and HUVECs. HAECs showed 2-fold
higher uptake of EPCR-NL than P-NL after both 2-hour and 3-
hour incubations, whereas a 4-fold higher uptake of EPCR-NL
was observed compared to B-NL. HUVECs showed a more than
a 3-fold higher MFI for EPCR-NL compared to the P-NL
formulation (2-hour and 3-hour incubations) and >5.5-fold
higher compared with the B-NL one (Fig. 3B). All results
showed statistical significance with P values generally below
0.01.
The strong interaction between EPCR-targeting liposomes
and the HRECs could also be visualized by confocal laser
scanning microscopy. From Z-stack projections, we were able
to detect strong fluorescent signal from the EPCR-targeting
liposomes, mainly in the intracellular compartment of the
HRECs (Fig. 4). In agreement with the flow cytometry results,
the signal from the HRECs that were incubated with the P-NL
formulation was much weaker (Fig. 4B) and in the case of the
B-NL, no signal was detected (Fig. 4C).
Reduction of ILs by Corticosteroid-Loaded EPCR-
Targeting Liposomes
To assess whether the enhanced uptake of EPCR-targeting
liposomes by endothelial cells resulted in an improved
therapeutic efficacy, we exposed HRECs and HAECs to
corticosteroid-loaded liposomes, PH loaded EPCR-NL1 and
dual-loaded (PP and PH) EPCR-NL2, and measured changes in
IL levels. We first stimulated increased IL expression in HRECs
and HAECs by culturing them in high glucose conditions. We
then tested the changes in the secretion levels of 3 different
inflammatory mediators with or without corticosteroid treat-
ment. IL-6 and IL-8 levels were significantly increased under
high glucose conditions for both HRECs and HAECs compared
to normal glucose conditions. The latter inflammatory effect
was significantly suppressed when the cells were treated with
free PH or PH encapsulated in the EPCR-targeting liposomes
(EPCR-NL1) (Fig. 5). According to the PH release profiles from
the liposomes, after 24 hours, less than 23% (22.5 6 3.4 % at
26 hours) of PH had been released, whereas at 48 hours,
approximately 40% (39.2 6 3.9 % at 48 hours) PH release had
occurred. This corresponds to 6 lM of PH released from the
EPCR-NL1 liposomes in 24 hours, followed by 4 lM released
over the next 24 hours (i.e., ~5 lM per day). EPCR-NL1
liposomes induced a similar anti-inflammatory effect, releasing
5 lM per day compared to the single 25-lM dose of free PH.
Single doses of free PH at 10 lM showed no effect on reducing
IL-6 and IL-8 levels in HRECs over 48 hours (see Supplementary
Fig. S4).
The dual-loaded (PP and PH) EPCR-targeting liposome
(EPCR-NL2) exhibited superior performance to EPCR-NL1 in
HRECs, indicating that PP was actively contributing to IL
reduction even though lipid anchored and at concentrations
(~2.4 lM) significantly lower than PH (~25 lM) in the
liposomes. For HRECs that were treated with EPCR-NL1, we
observed a 35% decrease in the IL-8 secretion both in day 1 and
day 2 after treatment. For EPCR-NL2, there was a 45% decrease
after day 1 and a 40% decrease after day 2. For IL-6, a 25%
decrease was observed for EPCR-NL1 after day 1 and day 2,
whereas for EPCR-NL2, this corresponded to a 42 and 39%
decrease (Fig. 5A). The PH loaded PEG surface-functionalized
nontargeting liposome P-NL1 exhibited significantly poorer
performance than both EPCR-NL1 and EPCR-NL2; more
specifically, a less than 15% decrease was observed for IL-6,
whereas no significant reduction in the IL-8 secretion was
observed (Fig. 5A). The difference between the formulations
can be attributed to the 3-fold lower uptake of P-NL compared
to EPCR-NL for HRECs (Fig. 3). Moreover, the performance of
the EPCR-NL1 compared to the nontargeting but drug loaded
liposomes was considerably better, with a 30% reduction in IL-
8 secretion both 1 and 2 days after treatment. The EPCR-NL2
formulation performed significantly better than either EPCR-
NL1 (P < 0.001) or the free drug (P < 0.01). HAECs responded
in a similar manner (Fig. 5B) with EPCR-NL1 inducing a 35%
decrease in the IL-8 secretion after day 1 and 37% after day 2,
whereas for EPCR-NL2, this was 40 and 45%. IL-6 secretion was
also inhibited with either EPCR-NL1 (20% and 25% decrease for
day 1 and day 2, respectively) or EPCR-NL2 treatment (30% and
25% decrease for day 1 and day 2, respectively). The P-NL1
formulation displayed inferior performance compared to the
EPCR-targeting formulation or the free PH but a better
performance than P-NL1 in HRECs. This likely reflects the
better uptake of P-NL by HAECs than HRECs (Fig. 3). We did
not observe similar behavior for IL-1b and were not able to
detect any difference in IL-1b secretion levels for any of the 5
different conditions for HRECs or HAECs (data not shown).
Inhibition of In Vitro Angiogenesis by
Corticosteroid-Loaded EPCR-targeting liposomes
In another attempt to explore the potential efficacy of targeting
EPCR, we tested the ability of EPCR-NL1 to inhibit angiogenesis
in vitro in an endothelial cell tube formation assay. Before the
efficacy studies, we tested the uptake of our liposomes by
HRECs in tube-like formations on Matrigel matrix. The results
were similar to what we previously observed from the uptake
studies in monolayer culture conditions; more specifically, we
detected strong fluorescent signal from EPCR-NL1, but weaker
signal from P-NL and no signal from B-NL (Fig. 6A–D). The
ability of HRECs to form tube-like structures was estimated by
calculating the number of segments and the total length of the
tube formations from images taken 8 hours after seeding the
cells on Matrigel. Incubating the cells with EPCR-NL1 and
EPCR-NL2 liposomes significantly inhibited tube-like forma-
tions compared to untreated cells, as shown by the decrease in
the total tube length (P < 0.05) and the number of segments (P
< 0.05 and P < 0.01) (Fig. 6E, 6F). Using the PH release
profiles (Fig. 1B) at 8 hours, we extrapolated that 7.8% of PH
has been released by ECPR-NL, corresponding to 3.9 lM. This
is significantly lower than the 50 lM of free PH required to
induce a similar effect on both tube length and the number of
segments (Fig. 6E, 6F). We did not observe any reduction in
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FIGURE 3. Flow cytometry evalution of liposome uptake in endothelial cells. (A) Flow cytometry evaluation of the association between EPCR-
targeting liposomes and endothelial cells. HRECs and HAECs were incubated with either EPCR-targeting liposomes (EPCR-NL), isotype IgG
functionalized liposomes (Iso-NL), or with EPCR-specific antibody (blocked EPCR) before adding the EPCR-targeting liposomes in order to block the
receptor. All MFI values are normalized to the MFI of the EPCR-NL. (B) Flow cytometry assessment of the liposome uptake by endothelial cells.
HRECS, HAECs, and HUVECs were incubated with either EPCR-NL, P-NL, or B-NL liposomes for 3 different incubation times: 1 hour, 2 hour, or 3
hour. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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tube length or the number of segments at 25 lM of free PH
(data not shown). Furthermore, P-NL1 treatment did not
induce any significant reduction in tube length or the number
of segments, even though PH release is similar to EPCR-NL
(7.9%). This indicates that the enhanced uptake of EPCR-
targeting liposomes leads to the improved efficacy of
prednisolone.
DISCUSSION
In this study, we showed for the first time that EPCR is
expressed by HRECs. It has been previously shown through
histologic studies in humans and baboons that all large vessels
and arteries express high levels of EPCR. In the brain
microvasculature, which can be used as direct comparison to
the retina, the expression was lower.14 The latter observation
provides a strong argument that EPCR should be expressed in
the human retinal endothelium as well. In an attempt to realize
the level of EPCR expression, we performed a comparative
study between HRECs and 2 other endothelial cell types,
HEACs and HUVECs, which have been shown to heavily
express the receptor in vitro.7 The flow cytometry and
immunoblotting assays indicated similar levels of EPCR
expression in all 3 different cell types, leading to the
conclusion that HRECs strongly express EPCR in vitro.
In order to investigate the potential of EPCR as a
nanomedicine target, we functionalized EPCR-specific antibody
onto the surface of liposomes to study the uptake of these
liposomes by HRECs, HAECs, and HUVECs in comparison to 2
nontargeting formulations. All of our formulations used
saturated lipids (DPPC and DPPE-Atto), which, due to higher
transition temperatures compared to unsaturated lipids, tend
to exhibit better stability.33 In our case with P-NL formulations,
we obtained a sustained PH release for up to 5 days, which was
not the case for unsaturated formulations that exhibited burst
release within the first 24 hours (data not shown). We also
incorporated cholesterol into all of our formulations, as it has
been previously shown that adding 30 to 40 mol% of
cholesterol can significantly improve the stability of lipo-
somes.34,35 Functionalizing the surface of the liposomes with
PEG is a widely used technique in order to not only improve
the circulation/residency time of nanocarriers34 but also to
improve nanocarrier mobility in the vitreous.36,37 We chose to
PEGylate our EPCR-targeting formulation due to the benefits of
PEG, but we also used a formulation with no surface
FIGURE 4. Confocal laser scanning microscopy of EPCR-targeting liposomes and HRECs: (A) HRECs incubated with EPCR-NL liposomes, (B) HRECs
incubated with P-NL liposomes, (C) HRECs incubated with B-NL liposomes. The first column shows actin staining (Phalloidin-TRITC), the second
column shows nucleus staining (TO-PRO-3), the third column shows liposomes (Atto 488), and the fourth column shows columns 1–3 merged.
Scale bar: 25 lm.
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functionalization (B-NL) to investigate how PEGylation would
affect the uptake of the liposomes by the cells.
In all the experiments, the EPCR-targeting liposomes
displayed significantly higher uptake than the control formu-
lations, even for incubation times as short as 1 hour. In order to
establish that it was actually EPCR-targeting that lead to the
enhanced uptake, EPCR was blocked before incubating with
the EPCR-targeting liposomes. This blockage lead to a 5-fold
inhibition of the uptake of the carrier with both HRECs and
HAECs (P < 0.0001), clearly indicating that EPCR targeting
drove the enhanced uptake.
The delivery of corticosteroid drugs to the posterior part of
the eye is a challenge because systemic administration is
associated with undesirable systemic side effects and eye drop
formulations have poor penetration. In contrast, injection of
corticosteroid into the vitreous is very effective in controlling
inflammation and macular edema secondary to diabetic
retinopathy and retinal vein occlusion. Diabetic retinopathy
is closely linked to hyperglycemia, low-grade chronic inflam-
mation, and elevated reactive oxygen species3,38,39 and is
dominated by the development of microaneurysms, hemor-
rhage, vascular leakage, macular edema, and preretinal
neovascularization at the back of the eye.3,4 Several studies
have indicated that there is a significant increase in the levels of
proangiogenic and proinflammatory factors and cytokines
(e.g., vascular endothelial growth factor, IL-8, TNF-a, IL-6, and
IL-1b) in the vitreous of a patient with diabetic retinopa-
thy.40–43 These findings have led to the emergence of several
novel treatment modalities based on the administration of
antivascular endothelial growth factor agents and corticoste-
roids to the diseased retina.44,45 Corticosteroids are an
attractive option due to their broad range of actions including
anti-inflammatory and antiangiogenic effects.46–49 Corticoste-
roid-loaded liposomes have been reported for several decades,
but drug loading efficacy and release rates have presented
significant challenges. The passive loading of hydrophilic
corticosteroids in liposomes initially resulted in very low
encapsulation efficiencies (<5%).50–52 Low loading can be
overcome by choosing amphipathic weak acid corticosteroids
and using a remote-loading approach. It has been shown that
using a calcium acetate ion gradient can lead to high loading
efficiencies of corticosteroid succinates, with 80% encapsula-
tion efficiency (EE) for betamethasone hemisuccinate, 100% EE
for hydrocortisone hemisuccinate, and 95% EE for methylpred-
nisolone hemisuccinate.25,52 In our case, we achieved a 70% EE
for PH that is lower compared to the other corticosteroids, and
this could likely be improved by optimizing the loading
parameters. Furthermore, palmitate corticosteroid derivatives
have also been studied since the late 1970s, with cortisol
palmitate, prednisolone palmitate, and dexamethasone palmi-
tate having been loaded into liposomes.53–55 In our case, we
loaded 5% molar concentration of PP into our liposomes with a
FIGURE 5. Secretion of IL-6 and IL-8 from endothelial cells normalized to the values of the untreated cells cultured under high glucose conditions
(dashed line). (A) Effect of free or loaded PH on HRECs. (B) Effect of free or loaded PH on HAECs. In both cases (HRECs and HAECs) cells were
exposed to free PH (25 lM) or PH loaded into either EPCR-targeting liposomes (EPCR-NL1), EPCR-targeting liposomes with PP in the membrane
(EPCR-NL2), or nontargeting liposomes (P-NL1). The cells were subjected to the different treatments for 4 hours, then washed, and supernatants
were collected 24 hours and 48 hour after the exposure. At the 24-hour timepoint, all liposomes had released ~6 lM of PH, whereas at 48 hours all
liposomes had released an additional ~4 lM (i.e., ~10 lM cumulative) of PH. All IL expression was normalized to cells cultured under high glucose
(dashed line). Cells cultured in 20 mM mannitol to represent healthy cells or stimulated cells treated with empty liposomes (EPCR-NL) were used as
controls. The significance levels are *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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45% EE, which is low compared to what has previously been
reported (up to 99% EE). However, these high EEs are
predominantly associated with large multilamellar liposomes
and not small unilamellar liposomes where extrusion results in
the structural rearrangement of the liposome bilayer, leading to
drug loss.56 In order to compensate for the loss of corticoste-
roid, we developed a dual-loaded liposome (EPCR-NL2) to see
if this resulted in an improved anti-inflammatory effect.
FIGURE 6. Liposome influence on HREC tube formation. (A) HRECs incubated with EPCR liposomes, (B) HRECs incubated with P-NL liposomes,
(C) HRECs incubated with B-NL, and (D) nontreated cells. Nuclei were stained with TO-PRO-3 and liposomes labeled with Atto 488. Scale bar: 250
lm. Quantification of tube formation by assesment of (E) the total tubule length and (F) and the number of segments 8 hours after seeding the cells
on Matrigel matrix. At this timepoint ~4 lM of PH has been released from the liposomes. *P < 0.05, **P < 0.01, ***P < 0.001).
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Cells cultured in high glucose conditions have previously
shown to have an inflammatory response.57–59 Corticosteroids
have repeatedly demonstrated inhibition of proinflammatory
cytokines in endothelial cells,58,60–63 and so we compared the
effect of prednisolone-loaded EPCR-targeting liposomes (EPCR-
NL1 and EPCR-NL2), nontargeting liposomes, and free drug on
endothelial cells. The outcome of these studies indicated that
EPCR-targeting liposomes and free drug inhibited the secretion
of cytokines, with the greatest impact being associated with
EPCR-NL2 for both HRECs and HAECs. These findings are in
accordance with older studies that have shown that lM
concentrations of dexamethasone can induce and approxi-
mately 50% decrease in the secretion of IL-6 and a 43%
decrease in IL-8 by stimulated endothelial cells,64,65 whereas
cortisol was reported to inhibit IL-6 by approximately 40%.64
Moreover, the performance of the EPCR-targeting liposomes
was superior to nontargeting liposomes, which could be
explained by the significantly higher uptake by HRECs and
HAECs. Glucocorticoid receptors are found mainly in the
cytoplasm66 and delivering drug payloads into cells should
maximize drug-receptor binding. We observed that EPCR-
targeting liposomes with significantly lower PH concentrations
(~5 lM per day) resulted in similar reductions in IL-6 and IL-8
expression as a single dose of free PH (25 lM). This
observation assumes that all the liposomes were endocytosed
by cells, which is unlikely. The concentrations of PH released
from the liposomes are therefore likely to be lower. Treating
stimulated HRECs with a single dose of free PH at 10 lM did
not induce any effect in the secretion of IL-6 or IL-8 over 48
hours (see Supplementary Fig. S4). This indicates that it was
the continuous intracellular release of PH which lead to an
improved effect with a 5-fold lower drug concentration. It has
been previously shown that corticosteroids remain active in
vitro for several days,67 can induce cytokine inhibition to
stimulated cells within 2 hours of exposure, and retain the
effect for up to 48 hours.64,65 This likely explains the sustained
effect observed for free PH. Moreover, EPCR-NL2 exhibited
significantly better performance compared to EPCR-NL1 and
free drug, which is interesting considering the low concentra-
tion of PP (~2.4 lM) and its poor water solubility. PP would
have to partition out of the liposomes, either through
interactions with proteins and/or phospholipid bilayers in
cells and vesicles, before readily reaching glucocorticoid
receptors. We did not observe differences in IL-1b secretion
levels for any of our culture conditions and treatments, even
though it has been previously reported.58,59
It has been shown that lM concentrations of triamcinolone
acetonide and cortisol as well as nM concentrations of
dexamethasone can induce up to a 50% inhibition in
endothelial cell tube formation in vitro.68–70 We observed no
inhibition in tube length or the number of segments for HRECs
when treated with free PH at 25 lM (data not shown), but did
observe inhibition of tube length and segment numbers at 50
lM (Fig. 6). EPCR-NL2 reduced tube length (20% decrease) and
significantly reduced the number of segments (50% decrease) 8
hours after seeding HRECs on Matrigel. EPCR-NL1 did not
perform as well and was comparable with free PH. No
significant differences were observed amongst the EPCR-
targeting liposomes and free PH. Based on the PH release
profile of EPCR-NL, by the time of our measurements (i.e., 8
hour), less than 8% of the drug had been released from the
liposomes, which means that with less than 4 lM of PH, we
induced a similar effect as 50 lM of free drug. The nontargeting
liposomes that exhibited a similar release profile as the EPCR-
targeting liposomes did not induce any effect in cell tube
formation. We believe that this enhanced effect occurs because
prednisolone is released intracellularly at higher concentra-
tions for EPCR-NL than P-NL, maximizing the probability of
drug-glucocorticoid receptor interactions. This results in a
lower therapeutic concentration of prednisolone required
compared to free prednisolone and a greater effect for EPCR-
NL due to the improved endocytosis compared to P-NL. EPCR-
NL liposomes showed a more profound effect on the
endothelial cell tube formation assay despite the increased
complexity of it compared to the two-dimensional cell
monolayer assay.
In conclusion, we demonstrated that HRECs strongly
express EPCR and that this receptor holds promise as a target
for enhanced drug delivery to endothelial cells due to the
significant increased uptake of EPCR-targeting liposomes in
endothelial cells compared to nontargeting liposomes. EPCR-
targeting liposomes showed significant reduction in IL-8 and IL-
6 secretion from HRECs and HAECs, as well as suppressed
HREC tube length and segment formation. Furthermore, EPCR-
targeting liposomes loaded with prednisolone in both the
bilayer and aqueous core showed greater anti-inflammatory
potential than the equivalent liposomes loaded with prednis-
olone in the core only or free drug. Further experiments are
required to determine if EPCR expression at the retina
endothelium is significant in vivo, whether EPCR is evenly
distributed or localized in the retina, and whether EPCR can be
used as a nanomedicine target in diseased retinas.
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